Old Web
English
Sign In
Acemap
>
authorDetail
>
Steven Sherman
Steven Sherman
University of Chicago
Internal medicine
Phosphatidylinositol
Phases of clinical research
Vemurafenib
Radiation therapy
2
Papers
18
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
2018
Vivek Subbiah
Shiraj Sen
Kenneth R. Hess
Filip Janku
David S. Hong
Soumen Khatua
Daniel D. Karp
Javier Munoz
Gerald S. Falchook
Roman Groisberg
Apostolia Maria Tsimberidou
Steven Sherman
Patrick Hwu
F. Meric-Bernstam
Show All
Source
Cite
Save
Citations (7)
A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies
2007
Molecular Cancer Therapeutics
Ravi Salgia
David K. Hong
Steven Sherman
Chann Ng
John Frye
Linda Janish
Mark J. Ratain
Razelle Kurzrock
Show All
Source
Cite
Save
Citations (11)
1